These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 3963859)
1. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia]. Esumi N; Todo S; Arakawa S; Imashuku S Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859 [TBL] [Abstract][Full Text] [Related]
2. [VP 16-213 in the treatment of acute leukemia in childhood]. Esumi N; Arakawa S; Imashuku S Gan To Kagaku Ryoho; 1983 Mar; 10(3):848-51. PubMed ID: 6576730 [TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
4. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia. Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970 [TBL] [Abstract][Full Text] [Related]
5. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
6. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia]. Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638 [TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687 [TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide/etoposide: effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse. Kalwinsky DK; Dahl GV; Mirro J; Look AT Cancer Treat Rep; 1985; 69(7-8):887-9. PubMed ID: 4016796 [TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA; J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813 [TBL] [Abstract][Full Text] [Related]
10. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine. Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431 [TBL] [Abstract][Full Text] [Related]
11. [Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia]. Koyama S; Saitou H; Kashiwaba M Rinsho Ketsueki; 1991 Jul; 32(7):736-42. PubMed ID: 1920837 [TBL] [Abstract][Full Text] [Related]
12. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [TBL] [Abstract][Full Text] [Related]
13. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665 [TBL] [Abstract][Full Text] [Related]
14. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Al Bahar S; Pandita R; Bavishi K; Kreze O Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411 [TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357 [TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
17. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia]. Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576 [TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
20. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia]. Koyama S; Itou S; Shibata A Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]